I-Glucosamine

-Delile

• Cishe iyasebenza ...
• Ubufakazi obanele bokukala ukusebenza kwe ...
• Ukuqapha okukhethekile nezixwayiso:

I-Glucosamine yikhemikhali elenzeka ngokwemvelo emzimbeni womuntu. Kusemanzini azungeze amalunga. I-Glucosamine nayo ikhona kwezinye izindawo emvelweni. Isibonelo, i-glucosamine esetshenziselwa izithako zokudla ivame ukutholakala kumagobolondo e-shellfish. I-Glucosamine nayo ingenziwa elebhu.

Kunezinhlobo ezahlukahlukene ze-glucosamine kufaka phakathi i-glucosamine sulfate, i-glucosamine hydrochloride, ne-N-acetyl glucosamine. Lawa makhemikhali ahlukene anokufana okuthile, kepha kungenzeka angabi nemiphumela efanayo lapho ethathwa njengesengezo sokudla. Iningi locwaningo lwesayensi nge-glucosamine lubandakanye i-glucosamine sulfate.

Eminye imikhiqizo ye-glucosamine ayilebulwa ngokunembile. Kwezinye izimo, inani le-glucosamine empeleni kumkhiqizo liye lahluka kusuka kokunye kuya ngaphezu kwe-100% yenani elishiwo ilebula lomkhiqizo. Eminye imikhiqizo ibiqukethe i-glucosamine hydrochloride lapho i-glucosamine sulfate ibhalwe ohlwini kwilebula.

I-Glucosamine sulfate ne-glucosamine hydrochloride zisetshenziselwa kakhulu i-osteoarthritis. I-Glucosamine nayo isetshenziselwa ezinye izimo eziningi, kepha abukho ubufakazi obuhle besayensi bokuxhasa lokhu kusetshenziswa.

Imibhalo Yemvelo Yemininingwane Ephelele ukukala ukusebenza ngokuncike ebufakazini besayensi ngokwesilinganiso esilandelayo: Okusebenzayo, Okungenzeka Kusebenze, Okungenzeka Kusebenze, Okungenzeka Kungasebenzi, Cishe Okungaphumeleli, Ukungasebenzi, Nobufakazi Obunganele Bokulinganisa.

Izilinganiso zokusebenza ze UGLUCOSAMINE zimi kanje:

Cishe iyasebenza ...

• I-osteoarthritis. Ucwaningo oluningi lukhombisa ukuthi ukuthatha i-glucosamine sulfate kunganikeza ukuphumula kobuhlungu kubantu abane-osteoarthritis, ikakhulukazi labo abane-osteoarthritis yamadolo. Kwabanye abantu, i-glucosamine sulphate ingasebenza kanye nemithi yezinhlungu zasesikhathini kanye nemithi kadokotela efana ne-acetaminophen noma ibuprofen. Kodwa imithi yezinhlungu isebenza ngokushesha, kuyilapho i-glucosamine sulfate ingathatha amasonto angu-4-8 ngaphambi kokuthi inikeze ukukhululeka kobuhlungu. Futhi, abantu abathatha i-glucosamine sulfate kaningi kusadingeka ukuthi baphuze imishanguzo yezinhlungu yokuqhuma kobuhlungu.
  
  Kunezinhlobo eziningana zemikhiqizo ye-glucosamine. Ucwaningo olubonisa inzuzo enkulu kakhulu yimikhiqizo equkethe i-glucosamine sulfate. Imikhiqizo equkethe i-glucosamine hydrochloride ibonakala ingasebenzi kahle ngaphandle kokuthi ithathwe ihlanganiswe nezinye izithako. Imikhiqizo eminingi iqukethe i-glucosamine ene-chondroitin, kepha abukho ubufakazi obuhle bokuthi le mikhiqizo isebenza kangcono kune-glucosamine sulfate iyodwa.
  
  I-Glucosamine sulfate akubonakali ivimbela abantu ekutholeni i-osteoarthritis.

Ubufakazi obanele bokukala ukusebenza kwe ...

• Ubuhlungu obuhlangene obubangelwa yimithi ebizwa ngokuthi i-aromatase inhibitors (i-aromatase inhibitor-induced arthralgias). Ucwaningo lwakuqala luphakamisa ukuthi ukuthatha inhlanganisela ye-glucosamine sulfate ne-chondroitin sulfate ngemithamo emibili noma emithathu ehlukanisiwe nsuku zonke amasonto angama-24 kunciphisa ubuhlungu kwabesifazane abathatha izidakamizwa ezehlisa amazinga e-estrogen omdlavuza webele wokuqala.
• Isifo senhliziyo. Abantu abathatha i-glucosamine bangaba nengozi ephansi yokuhlaselwa yisifo senhliziyo. Kepha akucaci ukuthi imuphi umthamo noma uhlobo lwe-glucosamine olungasebenza kahle kakhulu. Akucaci futhi ukuthi le ngozi engezansi ivela ku-glucosamine noma ekulandeleni imikhuba yokuphila enempilo.
• Ukucindezeleka. Ucwaningo lwakuqala lukhombisa ukuthi ukuthatha i-glucosamine hydrochloride amasonto ama-4 kungahle kuthuthukise izimpawu zokudangala kwabanye abantu abanokudangala.
• Isifo sikashukela. Abantu abathatha i-glucosamine bangaba nengozi ephansi yokuba nesifo sikashukela. Kepha akucaci ukuthi imuphi umthamo noma uhlobo lwe-glucosamine olungasebenza kahle kakhulu. Akucaci futhi ukuthi le ngozi engezansi ivela ku-glucosamine noma ekulandeleni imikhuba yokuphila enempilo.
• Izinga eliphakeme le-cholesterol noma amanye amafutha (lipids) egazini (hyperlipidemia). Ucwaningo lwakuqala luphakamisa ukuthi i-glucosamine hydrochloride ayithinti amazinga e-cholesterol noma we-triglyceride kubantu abane-cholesterol ephezulu.
• Ukuvuvukala kwesikhathi eside (ukuvuvukala) emkhakheni wokugaya ukudla (isifo sokuvuvukala kwamathumbu noma i-IBD). Kunobunye ubufakazi bokuqala bokuthi i-N-acetyl glucosamine ethathwe ngomlomo noma ngokweqile inganciphisa izimpawu ze-IBD ezinganeni ezine-Crohn disease noma i-ulcerative colitis.
• Isifo esithinta amathambo namalunga, imvamisa kubantu abanesifo selenium (isifo seKashin-Beck). Ubufakazi bokuqala bukhombisa ukuthi ukuthatha i-glucosamine hydrochloride kanye ne-chondroitin sulfate kunciphisa ubuhlungu futhi kuthuthukise ukusebenza komzimba kubantu abadala abanalesi simo. Ukuthatha i-glucosamine hydrochloride kuphela kungasebenza kanye nemithi yezinhlungu ezithengiswa ekhawunteni.
• Ubuhlungu emadolweni. Ucwaningo lokuqala lukhombisa ukuthi ukuthatha i-1500 mg ye-glucosamine sulfate nsuku zonke izinsuku ezingama-28 akubunciphisi ubuhlungu bamadolo kubagijimi abalandela ukulimala kwamadolo. Kepha kubonakala kuthuthukisa ukunyakaza kwamadolo. Kunobunye ubufakazi bakuqala bokuthi i-glucosamine hydrochloride ingadambisa izinhlungu kwabanye abantu abanobuhlungu obuqhutshwa njalo emadolweni.
• I-Multiple sclerosis (MS). Ucwaningo lokuqala lukhombisa ukuthi ukuthatha i-glucosamine sulfate ngomlomo nsuku zonke izinyanga eziyisithupha kunganciphisa ukubuyela emuva kwe-multiple sclerosis.
• Ukubuyiselwa emuva kokuhlinzwa. Ucwaningo lwakuqala lukhombisa ukuthi ukuthatha i-glucosamine sulphate akwenzi ngcono ukusebenza, ubuhlungu, nokusebenza kwabadlali besilisa abahlinzwa ukuze kulungiswe i-ACL edabukile. I-ACL iyi-ligament ebamba idolo endaweni lapho kuhamba.
• Isifo samathambo (RA). Ucwaningo lwakuqala lukhombisa ukuthi ukuthatha i-glucosamine hydrochloride kunganciphisa ubuhlungu kepha hhayi inani lamalunga avuvukile futhi abuhlungu.
• Unhlangothi. Ucwaningo lwangaphambilini luthole ukuthi abantu abathatha i-glucosamine bangaba nengozi ephansi kancane yokuba nesifo sohlangothi. Kepha akucaci ukuthi imuphi umthamo noma uhlobo lwe-glucosamine olungasebenza kahle kakhulu. Kepha akucaci ukuthi le ngozi engezansi ivela ku-glucosamine noma imikhuba yokuphila enempilo.
• Iqembu lezimo ezibuhlungu ezithinta ukuhlangana komhlathi nemisipha (izifo ze-temporomandibular noma i-TMD). Ucwaningo lwakuqala aluvumelani nokuthi ngabe i-glucosamine sulfate iyabunciphisa yini ubuhlungu kubantu abane-osteoarthritis yejoyini lomhlathi.
• Isikhumba esiguga.
• Ukuhlungu obusemhlane.
• Ukukhula okungewona umdlavuza emathunjini amakhulu naku-rectum (colorectal adenoma).
• Ukufa nganoma yisiphi isizathu.
• Ubuhlungu obuhlangene.
• Isifo esibuhlungu sesinye (i-Interstitial cystitis).
• Ukuphulukiswa kwesilonda.
• Ezinye izimo.

Kudingeka ubufakazi obengeziwe ukukala i-glucosamine sulfate yalokhu kusetshenziswa.

IGlucosamine yikhemikhali elitholakala emzimbeni womuntu. Isetshenziswa ngumzimba ukukhiqiza amanye amakhemikhali abandakanyekayo ekwakheni imisipha, imisipha, uqwanga, noketshezi olukhulu oluzungeze amalunga.

Amalunga ahlanganiswa uketshezi noqwanga olubazungezile. Kwabanye abantu abane-osteoarthritis, uqwanga luyehla lube mncane. Lokhu kubangela ukungqubuzana okuhlangene, izinhlungu nokuqina. Abaphenyi bacabanga ukuthi ukuthatha izithasiselo ze-glucosamine kungakhulisa uqwanga namalunga azungeze uketshezi noma kusize ukuvimbela ukonakala kwalezi zinto, noma mhlawumbe zombili.

Lapho ithathwa ngomlomo: I-Glucosamine sulfate iyi CISHE UVIKILE kubantu abadala abaningi. Glucosamine hydrochloride kuyinto OKUNGENZEKA UKUPHEPHA kubantu abadala abaningi lapho bethathwe ngokufanele kuze kube yiminyaka emi-2. I-N-acetyl glucosamine nayo OKUNGENZEKA UKUPHEPHA lapho ithathwa ngemithamo yama-3-6 amagremu nsuku zonke. I-Glucosamine ingadala imiphumela emibi emincane kufaka phakathi isicanucanu, isilungulela, isifo sohudo nokuqunjelwa. Imiphumela emibi ejwayelekile ukozela, ukusabela kwesikhumba, nekhanda.

Lapho isetshenziswa esikhunjeni: I-N-acetyl glucosamine iyi OKUNGENZEKA UKUPHEPHA lapho isetshenziswa kuze kube amasonto ayishumi.

Uma unikezwa njenge-enema (ohlangothini): I-N-acetyl glucosamine iyi OKUNGENZEKA UKUPHEPHA lapho isetshenziswa ngemithamo ka-3-4 amagremu nsuku zonke.

Lapho unikezwa njengesibhamu: I-Glucosamine sulfate iyi OKUNGENZEKA UKUPHEPHA lapho ufakwa emsipheni njengokudutshulwa kabili ngesonto kuze kube amasonto ayisithupha.

Ukuqapha okukhethekile nezixwayiso:

Ukukhulelwa noma ukuncelisa ibele: Alukho ulwazi olwanele oluthembekile lokwazi ukuthi ngabe i-glucosamine sulfate, i-glucosamine hydrochloride, noma i-N-acetyl glucosamine iphephile ukusetshenziswa uma ukhulelwe noma uncelisa ibele. Hlala ohlangothini oluphephile futhi ugweme ukusetshenziswa.

Isifuba Somoya: Kunombiko owodwa oxhumanisa ukuhlaselwa yisifuba somoya nokuthatha i-glucosamine. Akwaziwa kahle ukuthi ngabe i-glucosamine iyimbangela yokuhlaselwa yisifuba somoya. Kuze kube yilapho kwaziwa okuningi, abantu abane-asthma kufanele baqaphele ngokuthatha imikhiqizo equkethe i-glucosamine.

Isifo sikashukela: Olunye ucwaningo lwakuqala luphakamise ukuthi i-glucosamine ingakhuphula ushukela wegazi kubantu abanesifo sikashukela. Kepha ucwaningo lwakamuva noluthembeke kakhudlwana manje lukhombisa ukuthi i-glucosamine kubonakala ngathi ayikuthinti ukulawulwa kukashukela egazini kubantu abanesifo sikashukela sohlobo 2. IGlucosamine ibonakala iphephile kubantu abaningi abanesifo sikashukela, kepha ushukela wegazi kufanele ubhekwe ngeso lokhozi.

I-Glaucoma: I-Glucosamine ingakhuphula ingcindezi ngaphakathi kweso futhi ingayilimaza i-glaucoma. Uma une-glaucoma, khuluma nomhlinzeki wakho wezokunakekelwa kwempilo ngaphambi kokuthatha i-glucosamine.

I-cholesterol ephezulu: Olunye ucwaningo lwakuqala luphakamise ukuthi i-glucosamine ingakhuphula amazinga e-cholesterol. Kepha ucwaningo lwakamuva nolunokwethenjelwa manje lukhombisa ukuthi i-glucosamine akubonakali ikhuphula amazinga e-cholesterol.

Umfutho wegazi ophezulu: Olunye ucwaningo lwakuqala luphakamise ukuthi i-glucosamine ingakhuphula amazinga e-insulin. Kepha ucwaningo lwakamuva noluthembekile lukhombisa ukuthi i-glucosamine ayinyusi umfutho wegazi. Ukuze ube sohlangothini oluphephile, gada umfutho wegazi lakho eduze uma uthatha i-glucosamine sulfate futhi unengcindezi ephezulu yegazi.

Ukungezwani komzimba neshellfish: Kunokukhathazeka okuthile ukuthi imikhiqizo ye-glucosamine ingadala ukungezwani komzimba kubantu abazwela i-shellfish. I-Glucosamine ikhiqizwa kusuka kumagobolondo ezinhlanzi, ama-lobster kanye nonkala. Ukusabela okweqile kubantu abane-shellfish yokungezwani komzimba kubangelwa inyama ye-shellfish, hhayi igobolondo. Kepha abanye abantu bahlakulele ukusabela okweqile ngemuva kokusebenzisa izithako ze-glucosamine. Kungenzeka ukuthi eminye imikhiqizo ye-glucosamine ingahle ingcoliswe yingxenye yenyama ye-shellfish engadala ukusabela okweqile. Uma une-shellfish yokungezwani komzimba, khuluma nomhlinzeki wakho ngaphambi kokusebenzisa i-glucosamine.

Okukhulu

Ungathathi le nhlanganisela.

I-Warfarin (Coumadin)

I-Warfarin isetshenziselwa ukunciphisa ukujiya kwegazi. Kunemibiko eminingana ekhombisa ukuthi ukuthatha i-glucosamine nge-chondroitin noma ngaphandle kwayo kukhulisa umphumela we-warfarin, okwenza i-clot yegazi ihambe kancane. Lokhu kungadala ukulimala nokopha okungaba kubi kakhulu. Ungathathi i-glucosamine uma uthatha i-warfarin. Imithi eminingi yemvelo ingaxhumana ne-warfarin.

Maphakathi

Qaphela ngale nhlanganisela.

Imithi yomdlavuza (Topoisomerase II Inhibitors)

Eminye imishanguzo yokusebenza komdlavuza ngokunciphisa ukuthi amangqamuzana omdlavuza ashesha kangakanani ukuzikopa. Abanye ososayensi bacabanga ukuthi i-glucosamine ingavimba le mithi ekunciphiseni ukuthi amangqamuzana ama-tumor ngokushesha angazikopisha kanjani. Ukuthatha i-glucosamine kanye neminye imithi yomdlavuza kunganciphisa ukusebenza kwale mithi.

Eminye imithi esetshenziselwa umdlavuza ifaka i-etoposide (VP16, VePesid), teniposide (VM26), mitoxantrone, daunorubicin, ne-doxorubicin (Adriamycin).

Okuncane

Qaphela ngale nhlanganisela.

I-Acetaminophen (iTylenol, abanye)

Kunokukhathazeka okuthile ngokuthi ukuthatha i-glucosamine SULFATE ne-acetaminophen (iTylenol, abanye) ndawonye kungathinta ukuthi kusebenza kanjani ngakunye. Kepha imininingwane engaphezulu iyadingeka ukwazi ukuthi ngabe lokhu kuxhumana kuyinkinga enkulu. Okwamanje, ochwepheshe abaningi bathi kulungile ukuzisebenzisa zombili ndawonye.

Imithi yesifo sikashukela (Imithi elwa nesifo sikashukela)

Olunye ucwaningo lwakuqala lwaphakamisa ukuthi i-glucosamine ingakhuphula ushukela wegazi kubantu abanesifo sikashukela. Kepha ucwaningo lwakamuva noluthembeke kakhudlwana manje lukhombisa ukuthi i-glucosamine ibonakala ingathinti ukulawulwa kukashukela egazini kubantu abanesifo sikashukela sohlobo 2. Ngakho-ke, i-glucosamine mhlawumbe ayiphazamisi imithi yesifo sikashukela.

Eminye imithi esetshenziselwa isifo sikashukela ifaka i-glimepiride (Amaryl), i-glyburide (i-DiaBeta, i-Glynase PresTab, i-Micronase), i-insulin, i-pioglitazone (i-Actos), i-rosiglitazone (i-Avandia), i-chlorpropamide (i-Diabinese), i-glipizide (i-Glucotrol), i-tolbutamide (i-Orinase), .

I-chondroitin sulfate

Ukuthatha i-chondroitin sulfate kanye ne-glucosamine HYDROCHLORIDE kunganciphisa amazinga egazi e-glucosamine. Kodwa akucaci ukuthi lokhu kuzoguqula imiphumela ye-glucosamine hydrochloride.

Akukho ukuxhumana okwaziwayo nokudla.

Imithamo elandelayo ifundwe ocwaningweni lwesayensi:

NGOMLOMO:

• Okwe-osteoarthritis: I-Glucosamine SULFATE 1500 mg kanye ngosuku noma i-500 mg kathathu nsuku zonke, kungaba iyodwa noma ihlangene ne-400 mg ye-chondroitin sulphate kabili noma kathathu nsuku zonke, isetshenziswe iminyaka engafinyelela kwemithathu.

(3R, 4R, 5S, 6R) -3-Amino-6- (Hydroxymethyl) i-Oxane-2,4,5-Triol Hydrochloride, 2-Amino-2-Deoxy-Glucose, 2-Amino-2-Deoxy-Beta- D-Glucopyranose, 2-Amino-2-Deoxy-D-Glucose Sulfate, Acetylglucosamine, Acétylglucosamine, GlcNAc, 3-Amino-6- (Hydroxymethyl) Oxane-2,4,5-Triol Sulfate, Amino Monosaccharide, Chitosamine, Chlorhidrato Glucosamina, Chlorhydrate de Glucosamine, Chlorure de Potassium-Sulfate de Glucosamine, D-Glucosamine, D-Glucosamine HCl, D-Glucosamine Sulfate, D-Glucosamine Sulphate, G6S, Glucosamine HCl, Glucosamine KCl, Glucosamine Glucosamine I-Sulfate, i-Glucosamine Sulfate 2KCl, i-Glucosamine Sulfate-Potassium Chloride, iGlucosamine Sulphate, iGlucosamine Sulphate KCl, iGlucosamine-6-Phosphate, GS, Mono-Sulfated Saccharide, N-Acetil Glucosamina, N-Acéty Nlucamine Glucamine I-Acétylglucosamine, N-Acetyl D-Glucosamine, N-Acétyl D-Glucosamine, NAG, pGlcNAc, Poly-N-Acetyl Glucosamine, Poly-NAG, Poly- (1-> 3) -N-Acetyl-2-Amino-2- I-Deoxy-3-O-Beta-D-Gl ucopyranurosyl-4- (noma 6-) Sul, p-GlcNAc, Saccharide Mono-Sulfaté, Saccharide Sulfate, Sulfate de Glucosamine, Sulfate de Glucosamine 2KCl, SG, Sulfated Monosaccharide, Sulfated Saccharide, Sulfato de Glucosamina. 2-Amino-2-Deoxy-D-Glucosehydrochloride, 2-Amino-2-Deoxy-Beta-D-Glucopyranose, 2-Amino-2-Deoxy-Beta-D-Glucopyranose Hydrochloride, Amino Monosaccharide, Chitosamine Hydrochloride, Chlorlucidina , Chlorhydrate de Glucosamine, D-Glucosamine HCl, D-Glucosamine Hydrochloride, Glucosamine, Glucosamine HCl, Glucosamine KCl, Glucosamine-6-Phosphate. 2-Acetamido-2-deoxyglucose, Glucosamine, Glucosamine-6-phosphate, Glucosamine N-Acetyl, N-Acetil Glucosamina, N-Acétyl Glucosamine, N-Acétyl-Glucosamine, N-Acétylglucosamine, N-Acetyl D-Glucosamine I-Acétyl D-Glucosamine, i-NAG, i-NAG, i-pGlcNAc, i-Poly-N-Acetyl Glucosamine, i-Poly-NAG, i-p-GlcNAc.

Ukuze ufunde kabanzi ngokuthi le ndatshana ibhalwe kanjani, sicela ubheke ifayela le- Imibhalo Yemvelo Yemininingwane Ephelele indlela.

1. INkosi DE, Xiang J. Glucosamine / Chondroitin kanye nokufa kwabantu eQenjini laseMelika laseNANANES. J Am Board Fam Med. 2020; 33: 842-847. Buka okungaqondakali.
2. U-Lee DH, uCao C, uZong X, et al. I-Glucosamine neChondroitin Supplements kanye Nengozi yeColorectal Adenoma ne-Serrated Polyp. I-Cancer Epidemiol Biomarkers Okudlule. 2020; 29: 2693-2701. Buka okungaqondakali.
3. I-Kumar PNS, i-Sharma A, ne-Andrade C. Umshayeli wendiza, uphenyo olunelebula elisebenza ngokusebenza kweglucosamine ekwelapheni ukucindezeleka okukhulu. U-Asia J Psychiatr. 2020; 52: 102113. Buka okungaqondakali.
4. UMa H, uLi X, uZhou T, et al. Ukusetshenziswa kwe-Glucosamine, ukuvuvukala, kanye nokuthambekela kofuzo, kanye nesigameko sohlobo lwesifo sikashukela esingu-2: isifundo esizoba se-UK Biobank. Ukunakekelwa yisifo sikashukela. 2020; 43: 719-25. Buka okungaqondakali.
5. UBruyere O, Honvo G, uVeronese N, et al. Isincomo esibuyekeziwe se-algorithm sokuphathwa kwamadolo i-osteoarthritis avela ku-European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis, and Musculoskeletal Disease (ESCEO). I-Semin I-Arthritis Rheum. 2019 Disemba; 49: 337-50. Buka okungaqondakali.
6. INavarro SL, Levy L, Curtis KR, Lampe JW, Hullar MAJ. Ukushintshashintsha kweGut Microbiota nguGlucosamine noChondroitin esivivinyweni esingahleliwe, esiphindwe kabili esimpumputhe esivivinyweni sabantu. Ama-microorganisms. 2019 Novemba 23; 7. pii: E610. Buka okungaqondakali.
7. URainaino OF, Finamore R, uStellavato A, et al. Izithako zokudla zase-European chondroitin sulfate kanye ne-glucosamine: Ukuhlolwa kwekhwalithi nokuhleleka okuhlelekile uma kuqhathaniswa nemithi yokwelapha. I-Carbohydr Polym. 2019 Okthoba 15; 222: 114984. Buka okungaqondakali.
8. UHoban C, uByard R, uMusgrave I. Ukusabela okweqile kwezidakamizwa ekulungiseni i-glucosamine kanye ne-chondroitin e-Australia phakathi kuka-2000 no-2011. I-Postgrad Med J. 2019 Oct 9. pii: postgradmedj-2019-136957. Buka okungaqondakali.
9. UKolasinski SL, uNeogi T, uHochberg MC, et al. Umhlahlandlela we-2019 American College of Rheumatology / Arthritis Foundation wokuphathwa kwe-osteoarthritis yesandla, inqulu, nedolo. I-Arthritis Rheumatol. 2020 uFebhu; 72: 220-33. Buka okungaqondakali.
10. UTsuruta A, uHoriike T, uYoshimura M, uNagaoka I. Ukuhlolwa komphumela wokuphathwa kwe-glucosamine equkethe isengezo kuma-biomarkers we-cartilage metabolism kubadlali bebhola: Isifundo esilawulwa ngokungahleliwe se-placebo blind blind. I-Mol Med Rep. 2018 Okthoba; 18: 3941-3948. I-Epub 2018 Aug 17. Buka okungaqondakali.
11. I-Simental-Mendía M, Sánchez-García A, Vilchez-Cavazos F, Acosta-Olivo CA, Peña-Martínez VM, Simental-Mendía LE. Umphumela we-glucosamine ne-chondroitin sulphate ku-osteoarthritis ephawulekayo: ukubuyekezwa okuhlelekile nokuhlaziywa kwemeta kwezilingo ezilawulwa ngokungahleliwe ze-placebo. I-Rheumatol Int. 2018 Aug; 38: 1413-1428. I-Epub 2018 Jun 11. Ukubuyekeza. Buka okungaqondakali.
12. UGregori D, uGiacovelli G, uMinto C, et al. Inhlangano Yokwelashwa Kwemithi Ngokulawulwa Kwezinhlungu Kwesikhathi Eside Ezigulini ezine-Knee Osteoarthritis: Ukubuyekezwa okuhlelekile nokuhlaziywa kwe-Meta. JAMA. 2018 Dec 25; 320: 2564-2579. Buka okungaqondakali.
13. U-Ogata T, u-Ideno Y, u-Akai M, et al. Imiphumela ye-glucosamine ezigulini ezine-osteoarthritis yamadolo: ukubuyekezwa okuhlelekile nokuhlaziywa kwemeta. Umtholampilo Rheumatol. 2018 Septhemba; 37: 2479-2487. I-Epub 2018 Apr 30. Buka okungaqondakali.
14. UMa H, Li X, uSun D, ​​et al. Inhlangano yokusetshenziswa okujwayelekile kwe-glucosamine ngengozi yesifo senhliziyo: okucatshangelwa ukuthi kufundwe e-UK Biobank. BMJ. 2019 Meyi 14; 365: l1628. Buka okungaqondakali.
15. I-Vos BC, iLungu le-Landsmeer MLA, u-van Middelkoop M, et al. Imiphumela yesikhathi eside yokungenelela kwendlela yokuphila kanye ne-oral glucosamine sulphate ekunakekelweni okuyinhloko ngesehlakalo sedolo OA kwabesifazane abakhuluphele ngokweqile. I-Rheumatology (i-Oxford). 2017; 56: 1326-1334. Buka okungaqondakali.
16. UTsuji T, Yoon J, Kitano N, Okura T, Tanaka K. Imiphumela ye-N-acetyl glucosamine kanye ne-chondroitin sulfate supplementation ebuhlungwini bamadolo nokusebenza kwamadolo kwakho kubantu abadala baseJapan nabadala: i-randomized, double blind, isilingo esilawulwa yi-placebo. Umtholampilo Wokuguga Exp Res. 2016; 28: 197-205. Buka okungaqondakali.
17. URunhaar J, uDeroisy R, van Middelkoop M, et al. Indima yokudla nokuvivinya umzimba kanye ne-glucosamine sulfate ekuvikeleni i-knee osteoarthritis: Imiphumela eminye evela ekuvinjelweni kwe-knee Osteoarthritis esifundweni se-Overweight Females (PROOF). I-Semin I-Arthritis Rheum. 2016; 45 (4 Isipelesi): S42-8. Buka okungaqondakali.
18. URoman-Blas JA, uCastañeda S, uSánchez-Pernaute O, et al. Ukwelashwa Okuhlanganisiwe Ne-Chondroitin Sulfate ne-Glucosamine Sulfate Show Akukhombisi Ukuphakama Kwe-Placebo Yokunciphisa Ubuhlungu Obusebenzayo Nokukhubazeka Okusebenzayo Ezigulini Ezine-Knee Osteoarthritis: I-Multicenter Yezinyanga Eziyisithupha, Engahleliwe, Eyimpumputhe, Isivivinyo Somtholampilo Esilawulwa Nge-Placebo. I-Arthritis Rheumatol. U-2017; 69: 77-85. Buka okungaqondakali.
19. Kongtharvonskul J, Anothaisintawee T, McEvoy M, Attia J, Woratanarat P, Thakkinstian A. Ukusebenza nokuphepha kwe-glucosamine, i-diacerein, nama-NSAID emadolweni e-osteoarthritis: ukubuyekezwa okuhlelekile nokuhlaziywa kwe-meta-analysis. I-Eur J Med Res. 2015; 20: 24. Buka okungaqondakali.
20. I-Kanzaki N, i-Ono Y, i-Shibata H, i-Moritani T. Glucosamine equkethe isengezo ithuthukisa imisebenzi ye-locomotor ezifundweni ezinobuhlungu bamadolo: isifundo esilawulwa ngokungahleliwe, esimpumputhe, esilawulwa nge-placebo. Ukuguga Kwe-Clin Interv. 2015; 10: 1743-53. Buka okungaqondakali.
21. IGueniche A, uCastiel-Higounenc I. Ukusebenza kweGlucosamine Sulphate ekugugeni kwesikhumba: Imiphumela evela ku-ex vivo Anti-Aging Model kanye ne-Clinical Trial. Isikhumba Pharmacol Physiol. 2017; 30: 36-41. Buka okungaqondakali.
22. I-Eraslan A, i-Ulkar B.Glucosamine ukwengezwa ngemuva kokwakhiwa kabusha kwe-ligament yangaphakathi kubadlali: isilingo esilawulwa ngokungahleliwe. Res Ezemidlalo Med. 2015; 23: 14-26. Buka okungaqondakali.
23. U-Esfandiari H, Pakravan M, Zakeri Z, et al. Umphumela we-glucosamine ekucindezelekeni kwe-intraocular: isilingo somtholampilo esingahleliwe. Iso. 2017; 31: 389-394.
24. UMurphy RK, uJaccoma EH, uRice RD, uKetzler L.Glucosamine njengesiKhathi Sengozi Esingaba khona seGlaucoma. Faka i-Ophthalmol Vis Sci 2009; 50: 5850.
25. U-Eriksen P, uBartels EM, u-Altman RD, uBliddal H, uJuhl C, uChristensen R. Ingozi yokwenzelela nomkhiqizo bachaza ukungahambelani okubonwayo ekuvivinyweni kwe-glucosamine ukuthola impumuzo ye-osteoarthritis: ukuhlaziywa kwe-meta kwezilingo ezilawulwa yi-placebo. I-Arthritis Care Res (iHoboken). 2014; 66: 1844-55. Buka okungaqondakali.
26. USingh JA, uNoorbaloochi S, uMacDonald R, uMaxwell LJ. I-Chondroitin ye-osteoarthritis. ICochrane Database Syst Rev. 2015 Jan 28; 1: CD005614. Buka okungaqondakali.
27. UBruyère O, Cooper C, uPelletier JP, et al. Isitatimende sokuvumelana nge-European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) algorithm yokuphathwa kwamadolo i-osteoarthritis-Kusuka emithini esuselwe ebufakazini iye esimeni sempilo yangempela. I-Semin I-Arthritis Rheum. 2016; 45 (4 Suppl): S3-11. Buka okungaqondakali.
28. UKimball AB, uKaczvinsky JR, Li J, et al. Ukwehliswa ekubukekeni kwe-hyperpigmentation ebusweni ngemuva kokusetshenziswa kwezithambisi ngenhlanganisela ye-niacinamide ne-N-acetyl glucosamine: imiphumela yesilingo esilawulwa ngokungahleliwe, esingaboni kabili, esilawulwa yimoto. UBr J Dermatol 2010; 162: 435-41. Buka okungaqondakali.
29. UMadhu K, uChanda K, uSaji MJ. Ukuphepha nokusebenza kwe-Curcuma longa kukhishwe ekwelapheni i-knee osteoarthritis ebuhlungu: isilingo esilawulwa ngokungahleliwe. I-Inflammopharmacology 2013; 21: 129-36. Buka okungaqondakali.
30. UVetter G. [Ukwelashwa ngezihloko kwama-arthroses nama-glucosamines (Dona 200)]. UMunch Med Wochenschr 1969; 111: 1499-502. Buka okungaqondakali.
31. I-Setnikar I, i-Giacchetti C, i-Zanolo G. Pharmacokinetics ye-glucosamine enjeni nasemuntwini. I-Arzneimittelforschung 1986; 36: 729-35. Buka okungaqondakali.
32. UBasak M, uJoseph S, uJoshi S, uSawant S. Ukuqhathaniswa kokutholakala kokukhishwa kwesikhathi okuvelwayo kanye nokwakhiwa kwe-glucosamine sulfate egcwele i-powder - isifundo semithamo eminingi, okungahleliwe, se-crossover. I-Int J Clin Pharmacol Ther 2004; 42: 597-601. Buka okungaqondakali.
33. I-Phitak T, i-Pothacharoen P, i-Kongtawelert P. Ukuqhathanisa imiphumela ye-glucose etholakele ekonakaleni kwe-cartilage. I-BMC Musculoskelet Disord 2010; 11: 162. Buka okungaqondakali.
34. I-Setnikar I, i-Cereda R, i-Pacini MA, i-Revel L. Izici ezingasebenzi ze-glucosamine sulfate. I-Arzneimittelforschung 1991; 41: 157-61. Buka okungaqondakali.
35. ISumantran VN, Chandwaskar R, Joshi AK, Boddul S, Patwardhan B, Chopra A, Wagh UV. Ubudlelwano phakathi kwemiphumela ye-chondroprotective ne-antiinfigueatory ye-Andania somnifera impande kanye ne-glucosamine sulphate ku-osteoarthritic cartilage in vitro. I-Phytother Res 2008; 22: 1342-8. Buka okungaqondakali.
36. I-Setnikar I, i-Pacini MA, i-Revel L. imiphumela ye-antiarthritic ye-glucosamine sulfate efundwe kumamodeli wezilwane. I-Arzneimittelforschung 1991; 41: 542-5. Buka okungaqondakali.
37. UBassleer C, uHenrotin Y, uFranchimont P. Ukuhlolwa kwe-In-vitro kwezidakamizwa eziphakanyiswe njengama-chondroprotective agents. I-Int J Tissue React 1992; 14: 231-41. Buka okungaqondakali.
38. UCalamia V, uRuiz-Romero C, uRocha B, uFernández-Puente P, uMateos J, uMontell E, uVergés J, uBlanco FJ. Ucwaningo lwe-Pharmacoproteomic lwemiphumela ye-chondroitin ne-glucosamine sulfate kuma-chondrocyte we-articular womuntu. I-Arthritis Res Ther 2010; 12: R138. Buka okungaqondakali.
39. IGraeser AC, Giller K, Wiegand H, Barella L, Boesch Saadatmandi C, Rimbach G. Synergistic chondroprotective umphumela we-alpha-tocopherol, i-ascorbic acid, ne-selenium kanye ne-glucosamine ne-chondroitin ku-oxidant eyenzelwe ukufa kweseli nokuvinjelwa kwe-matrix metalloproteinase-3 --izifundo kuma-chondrocyte akhulisiwe. Ama-molecule. U-2009; 15: 27-39. Buka okungaqondakali.
40. UMurphy RK, uKetzler L, uRice RD, uJohnson SM, uDoss MS, uJaccoma EH. Izithako zomlomo ze-glucosamine njenge-ocular hypertensive agent. UJAMA Ophthalmol 2013; 131: 955-7. Buka okungaqondakali.
41. I-Swinburne LM. I-Glucosamine sulphate ne-osteoarthritis. ILancet 2001; 357: 1617. Buka okungaqondakali.
42. I-Akarasereenont P, Chatsiricharoenkul S, Pongnarin P, Sathirakul K, Kongpatanakul S. Bioequivalence isifundo se-500 mg glucosamine sulphate kumavolontiya anempilo aseThai. UJ Med Assoc Thai 2009; 92: 1234-9. Buka okungaqondakali.
43. Chopra A, Saluja M, Tillu G, Venugopalan A, Sarmukaddam S, Raut AK, Bichile L, Narsimulu G, Handa R, Patwardhan B. Ukuhlolwa Kokulawulwa Okungahleliwe Kokuhlolwa Kwamafomu Ase-Ayurvedic ku-Symptomatic Osteoarthritis Knees: A Government of India NMITLI Project Project . I-Evid Based Complement Alternat Med 2011; 2011: 724291. Buka okungaqondakali.
44. I-Wangroongsub Y, Tanavalee A, Wilairatana V, Ngarmukos S. Imiphumela yomtholampilo engaqhathaniswa phakathi kwe-glucosamine sulfate-potassium chloride kanye ne-glucosamine sulfate sodium chloride ezigulini ezine-osteoarthritis yamadolo emnene futhi elinganiselayo: isifundo esingahleliwe, esimpumputhe kabili. UJ Med Assoc Thai 2010; 93: 805-11. Buka okungaqondakali.
45. ISmidt D, Torpet LA, Nauntofte B, Heegaard KM, Pedersen AM. Izinhlangano phakathi kwamazinga okugeleza kwamalabali kanye nawo wonke, izifo zesistimu nemithi kusampula yabantu abadala. I-Community Dent Oral Epidemiol 2010; 38: 422-35. Buka okungaqondakali.
46. USimon RR, uMarks V, iLeeds AR, noAnderson JW. Ukubuyekezwa okuphelele kokusetshenziswa komlomo kwe-glucosamine nemiphumela ku-glucose metabolism kubantu abajwayelekile nabanesifo sikashukela. Isifo Sikashukela Metab Res Rev 2011; 27: 14-27. Buka okungaqondakali.
47. UWilkens, P., Scheel, I. B., Grundnes, O., Hellum, C., noStorheim, K. Umphumela we-glucosamine ekukhubazekeni okuhlobene nobuhlungu ezigulini ezinobuhlungu obungapheli obubuhlungu emuva kanye ne-lumbar osteoarthritis ekhubazekayo: isilingo esilawulwa ngokungahleliwe. I-JAMA 2010; 304: 45-52. Buka okungaqondakali.
48. UGreenlee H, uCrew KD, Shao T, Kranwinkel G, Kalinsky K, Maurer M, Brafman L, Insel B, Tsai WY, Hershman DL. Isigaba II sokufunda nge-glucosamine ne-chondroitin ku-aromatase inhibitor ehambisana nezimpawu ezihlangene zabesifazane abanomdlavuza webele. Ukusekela Umdlavuza Wokunakekela 2013; 21: 1077-87. Buka okungaqondakali.
49. I-Nieman DC, i-Shanely RA, i-Luo B, i-Dew D, i-MP ye-Meaney, u-Sha W. Isengezo sokuthengisa esidayiswayo sidambisa izinhlungu ezihlangene kubantu abadala bomphakathi: icala lomphakathi elilawulwa izimpumputhe, elilawulwa yi-placebo Umsoco J 2013; 12: 154. Buka okungaqondakali.
50. UFransen M, Agaliotis M, Nairn L, Votrubec M, Bridgett L, Su S, Jan S, Mashi L, Edmonds J, Norton R, Woodward M, Usuku R; ILEGS ifunda iqembu elibambisanayo. I-Glucosamine ne-chondroitin yamadolo i-osteoarthritis: isilingo somtholampilo esilawulwa nge-placebo esilawulwa kabili esingahloliwe semithi eyodwa kanye nenhlanganisela. U-Ann Rheum Dis 2015; 74: 851-8. Buka okungaqondakali.
51. Chopra A, Saluja M, Tillu G, Sarmukkaddam S, Venugopalan A, Narsimulu G, Handa R, Sumantran V, Raut A, Bichile L, Joshi K, Patwardhan B. Umuthi we-Ayurvedic unikeza enye indlela enhle yokuthola i-glucosamine ne-celecoxib ekwelapheni uphawu lwe-osteoarthritis yamadolo: isilingo esingahleliwe, esingaboni kabili, esilawulwa ngokulingana kwesidakamizwa. I-Rheumatology (Oxford) 2013; 52: 1408-17. Buka okungaqondakali.
52. ULevin RM, uKrieger NN, noWinzler RJ. I-Glucosamine nokubekezelelana kwe-acetylglucosamine kumuntu. UJ Lab Clin Med 1961; 58: 927-932.
53. U-Wu H, u-Liu M, u-Wang S, u-Zhao H, u-Yao W, u-Feng W, u-Yan M, u-Tang uY, u-Wei M. Ukuqhathanisa ukutholakala kokuzila ukudla kanye nezakhiwo ze-pharmacokinetic zokwenziwa kwe-2 kwe-glucosamine hydrochloride kumavolontiya amadala angamaShayina aphilile. Arzneimittelforschung. 2012 Aug; 62: 367-71. Buka okungaqondakali.
54. Liang CM, Tai MC, Chang YH, Chen YH, Chen CL, Chien MW, Chen JT. I-Glucosamine ivimbela ukwanda kwe-epidermal factor-induction nokwanda komjikelezo weseli kumaseli we-retinal pigment epithelial cell. I-Mol Vis 2010; 16: 2559-71. Buka okungaqondakali.
55. I-Yomogida S, i-Hua J, i-Sakamoto K, i-Nagaoka I. I-Glucosamine icindezela ukukhiqizwa kwe-interleukin-8 kanye nokuvezwa kwe-ICAM-1 ngamaseli e-TNF-alpha-evuselelwe ama-colonic epithelial HT-29 amaseli. I-Int J Mol Med 2008; 22: 205-11. Buka okungaqondakali.
56. UKim CH, uCheong KA, iCD Park, uLee AY. I-Glucosamine ithuthukise izilonda zesikhumba ezinjenge-atopic dermatitis ku-NC / Nga amagundane ngokuvimbela ukukhula kweseli kwe-Th2. IScand J Immunol 2011; 73: 536-45. Buka okungaqondakali.
57. UJu Y, Hua J, Sakamoto K, Ogawa H, Nagaoka I.Glucosamine, okwenzeka ngokwemvelo kwe-amino monosaccharide modulates LL-37-indased endothelial cell activation. I-Int J Mol Med 2008; 22: 657-62. Buka okungaqondakali.
58. I-Qiu W, i-Su Q, i-Rutledge AC, i-Zhang J, i-Adeli K. Glucosamine eyenziwe nge-endoplasmic reticulum stress inciphisa i-apolipoprotein B100 synthesis ngokusayina kwe-PERK. UJ Lipid Res 2009; 50: 1814-23. Buka okungaqondakali.
59. UJu Y, Hua J, Sakamoto K, Ogawa H, Nagaoka I. Ukushintshwa kwe-TNF-alpha-indosed endothelial cell activation yi-glucosamine, i-amino monosaccharide eyenzeka ngokwemvelo. I-Int J Mol Med 2008; 22: 809-15. Buka okungaqondakali.
60. U-Ilic MZ, uMartinac B, uSamiric T, uHandley CJ. Imiphumela ye-glucosamine ekulahlekelweni yi-proteoglycan nge-tendon, ligament kanye namasiko wokuhlola ama-capsule ahlangene. I-Osteoarthritis Cartilage 2008; 16: 1501-8. Buka okungaqondakali.
61. UToegel S, Wu SQ, Piana C, Unger FM, Wirth M, Goldring MB, Gabor F, Viernstein H. Ukuqhathanisa phakathi kwemiphumela ye-chondroprotective ye-glucosamine, i-curcumin, ne-diacerein kuma-chondrocyte e-IL-1beta akhuthazwe yi-C-28 / I2. I-Osteoarthritis Cartilage 2008; 16: 1205-12. Buka okungaqondakali.
62. I-Lin YC, i-Liang YC, i-Sheu MT, i-Lin YC, i-Hsieh MS, i-Chen TF, i-Chen CH. Imiphumela ye-Chondroprotective ye-glucosamine efaka i-p38 MAPK ne-Akt signaling pathways. IRheumatol Int 2008; 28: 1009-16. Buka okungaqondakali.
63. IScotto d'Abusco A, iPoliti L, iGiordano C, iScandurra R. Isisetshenziswa se-peptidyl-glucosamine sithinta umsebenzi we-IKKalpha kinase kuma-chondrocyte womuntu. I-Arthritis Res Ther 2010; 12: R18. Buka okungaqondakali.
64. UShikhman AR, uBrinson DC, uValbracht J, uLotz MK. Imiphumela ehlukile yemethabolic ye-glucosamine ne-N-acetylglucosamine kuma-chondrocyte womuntu wobuciko. I-Osteoarthritis Cartilage 2009; 17: 1022-8. Buka okungaqondakali.
65. Uitterlinden EJ, Koevoet JL, Verkoelen CF, Bierma-Zeinstra SM, Jahr H, Weinans H, Verhaar JA, van Osch GJ. I-Glucosamine yandisa ukukhiqizwa kwe-hyaluronic acid kuma-osteoarthritic synovium explants. I-BMC Musculoskelet Disord 2008; 9: 120. Buka okungaqondakali.
66. Hong H, Park YK, Choi MS, Ryu NH, Ingoma DK, Suh SI, Nam KY, Park GY, Jang BC. Ukwehluka kokulawulwa phansi kwe-COX-2 ne-MMP-13 kuma-fibroblast esikhumba somuntu yi-glucosamine-hydrochloride. J I-Dermatol Sci 2009; 56: 43-50. Buka okungaqondakali.
67. I-Wu YL, Kou YR, Ou HL, Chien HY, Chuang KH, Liu HH, Lee TS, Tsai CY, Lu ML. Ukulawulwa kwe-Glucosamine kokuvuvukala okuphakathi kwe-LPS kumaseli womuntu we-bronchial epithelial. I-Eur J Pharmacol 2010; I-635 (1-3): 219-26. Buka okungaqondakali.
68. Imagawa K, de Andrés MC, Hashimoto K, Pitt D, Itoi E, Goldring MB, Roach HI, Oreffo RO. Umphumela we-epigenetic we-glucosamine kanye ne-nuclear factor-kappa B (NF-kB) inhibitor kuma-chondrocyte ayisisekelo abantu - imiphumela ye-osteoarthritis. I-Biochem Biophys Res Commun 2011; 405: 362-7. Buka okungaqondakali.
69. I-Yomogida S, i-Kojima Y, i-Tsutsumi-Ishii Y, i-Hua J, i-Sakamoto K, i-Nagaoka I. I-Glucosamine, i-amino monosaccharide eyenzeka ngokwemvelo, icindezela i-dextran sulfate colitis eyenziwe nge-sodium kumagundane. I-Int J Mol Med 2008; 22: 317-23. Buka okungaqondakali.
70. I-Sakai S, i-Sugawara T, i-Kishi T, i-Yanagimoto K, i-Hirata T. Umphumela we-glucosamine kanye nezinhlanganisela ezihlobene nokwehliswa kwamangqamuzana omzimba nokuvuvukala kwezindlebe okubangelwa yi-dinitrofluorobenzene kumagundane. Impilo Sci 2010; 86 (9-10): 337-43. Buka okungaqondakali.
71. IHwang MS, iBaek WK. I-Glucosamine inciphisa ukufa kweseli okuzenzakalelayo ngokukhuthaza ukucindezeleka kwe-ER kumaseli womdlavuza womuntu we-glioma. I-Biochem Biophys Res Commun 2010; 399: 111-6. Buka okungaqondakali.
72. IPark JY, iPark JW, iSuh SI, iBaek WK. I-D-glucosamine phansi-ilawula i-HIF-1alpha ngokuvimbela ukuhumusha kwamaprotheni kumaseli womdlavuza we-DU145. I-Biochem Biophys Res Commun 2009; 382: 96-101. Buka okungaqondakali.
73. I-Chesnokov V, i-Sun C, i-Itakura K. I-Glucosamine icindezela ukwanda kwamangqamuzana e-prostate carcinoma DU145 ngokuvimbela ukusayinwa kwe-STAT3. ICancer Cell Int 2009; 9:25. Buka okungaqondakali.
74. Tsai CY, Lee TS, Kou YR, Wu YL. I-Glucosamine ivimbela ukukhiqizwa kwe-IL-1beta-mediated IL-8 kumaseli womdlavuza wesibeletho ngokunqanyulwa kwe-MAPK. I-J Cell Biochem 2009; 108: 489-98. Buka okungaqondakali.
75. UKim DS, iPark KS, uJeong KC, uLee BI, uLee CH, uKim SY. I-Glucosamine iyi-chemo-sensitizer esebenzayo nge-transglutaminase 2 inhibition. I-Cancer Lett 2009; 273: 243-9. Buka okungaqondakali.
76. UNaito K, Watari T, Furuhata A, Yomogida S, Sakamoto K, Kurosawa H, Kaneko K, Nagaoka I. Ukuhlolwa komphumela we-glucosamine kwimodeli yokuhlola yama-rat osteoarthritis. Impilo Sci 2010; 86 (13-14): 538-43. Buka okungaqondakali.
77. I-Weiden S ne-Wood IJ. Isiphetho se-glucosamine hydrochloride sijojowe ngomjovo kumuntu. UJ Clin Pathol 1958; 11: 343-349.
78. Satia JA, Littman A, Slatore CG, Galanko JA, White E. Associations of herbal and specialty supplements with lung and colorectal cancer risk in the VITamins and Lifestyle study. I-Cancer Epidemiol Biomarkers Prev 2009; 18: 1419-28. Buka okungaqondakali.
79. I-Audimoolam VK, Bhandari S. Acute interstitial nephritis ebangelwa yi-glucosamine. Ukufakelwa kweNephrol Dial 2006; 21: 2031. Buka okungaqondakali.
80. Ossendza RA, Grandval P, Chinoune F, Rocher F, Chapel F, Bernardini D. [Acute cholestatic hepatitis ngenxa yeglucosamine forte]. IGastroenterol Clin Biol. 2007 Ephreli; 31: 449-50. Buka okungaqondakali.
81. UWu D, uHuang Y, uGu Y, uFan W. Ukusebenza kwamalungiselelo ehlukene we-glucosamine ekwelapheni i-osteoarthritis: ukuhlaziywa kwe-meta kokuhlolwa okulawulwa ngokungahleliwe, okuyimpumputhe, nokulawulwa kwe-placebo. I-Int J Clin Pract 2013; 67: 585-94. Buka okungaqondakali.
82. I-Provenza JR, iShinjo SK, iSilva JM, iPeron CR, iRocha FA. I-glucosamine ehlanganisiwe ne-chondroitin sulfate, kanye noma kathathu nsuku zonke, ihlinzeka nge-analgesia efanelekile emtholampilo ku-knee osteoarthritis. I-Clin Rheumatol 2015; 34: 1455-62. Bheka okungaqondakali.
83. I-Kwoh CK, i-Roemer FW, i-Hannon MJ, i-Moore CE, i-Jakicic JM, i-Guermazi A, i-Green SM, i-Evans RW, i-Boudreau R. Umphumela we-glucosamine yomlomo ekwakhiweni okuhlangene kubantu abanezinhlungu ezingapheli zamadolo: isilingo somtholampilo esilawulwa ngokungahleliwe. I-Arthritis Rheumatol. 2014 Ephreli; 66: 930-9. Buka okungaqondakali.
84. von Felden J, Montani M, Kessebohm K, Stickel F. Ukulimala kwesibindi okubangelwa izidakamizwa okulingisa i-hepatitis ezenzakalelayo ngemuva kokudla izithako zokudla eziqukethe i-glucosamine ne-chondroitin sulfate. I-Int J Clin Pharmacol Ther 2013; 51: 219-23. Buka okungaqondakali.
85. UHochberg MC, uMartel-Pelletier J, uMonfort J, uMöller I, uCastillo JR, u-Arden N, uBerenbaum F, uBlanco FJ, uConaghan PG, uDoménech G, uHenrotin Y, uPap T, uRichette P, uSawitzke A, uDu Souich P, uPelletier JP ; egameni le-MOVES Investigation Group. I-chondroitin sulphate ne-glucosamine ehlanganisiwe ye-osteoarthritis yamadolo ebuhlungu: isilingo se-multicentre, randomized, blind-blind, non-inferiority versus celecoxib. U-Ann Rheum Dis 2016; 75: 37-44. Buka okungaqondakali.
86. UCerda C, Bruguera M, Parés A. Hepatotoxicity ehambisana ne-glucosamine ne-chondroitin sulfate ezigulini ezinesifo esingalapheki sesibindi. Umhlaba J Gastroenterol 2013; 19: 5381-4. Buka okungaqondakali.
87. UFox BA, uStephens MM. I-Glucosamine hydrochloride yokwelashwa kwezimpawu ze-osteoarthritis. Ukuguga Kwe-Clin Interv 2007; 2: 599-604. Buka okungaqondakali.
88. UVlad, S. C., LaValley, M. P., McAlindon, T. E., noFelson, D. T. Glucosamine wezinhlungu ze-osteoarthritis: kungani imiphumela yezilingo ihlukile? I-Arthritis Rheum 2007; 56: 2267-2277. Buka okungaqondakali.
89. Reginster, J. Y. Ukusebenza kwe-glucosamine sulfate ku-osteoarthritis: ukungqubuzana kwezezimali nokungahambisani nezimali. I-Arthritis Rheum 2007; 56: 2105-2110. Buka okungaqondakali.
90. UFrestedt, J. L., Walsh, M., Kuskowski, M. A., noZenk, J. L. Isengezo semvelo samaminerali sinikeza ukukhululeka kwizimpawu zamadolo i-osteoarthritis: isilingo somshayeli esilawulwa ngokungahleliwe. Umsoco J 2008; 7: 9. Buka okungaqondakali.
91. UYue, J., Yang, M., Yi, S., Dong, B., Li, W., Yang, Z., Lu, J., Zhang, R., no-Yong, J. Chondroitin sulfate kanye / noma i-glucosamine hydrochloride yesifo sikaKashin-Beck: isifundo esilawulwa yiqoqo elilawulwa ngokungahleliwe. I-Osteoarthritis.Cartilage. 2012; 20: 622-629. Buka okungaqondakali.
92. UKanzaki, N., Saito, K., Maeda, A., Kitagawa, Y., Kiso, Y., Watanabe, K., Tomonaga, A., Nagaoka, I., noJamaguchi, H. Umphumela wesengezo sokudla. equkethe i-glucosamine hydrochloride, i-chondroitin sulphate ne-quercetin glycosides ku-osteoarthritis enophawu: isifundo esilawulwa ngokungahleliwe, esiyimpumputhe, esilawulwa yi-placebo. J.Sci.Izolimo Zokudla. 3-15-2012; 92: 862-869. Buka okungaqondakali.
93. UWandel, S., Juni, P., Tendal, B., Nuesch, E., Villiger, PM, Welton, NJ, Reichenbach, S., noTrelle, S. Imiphumela ye-glucosamine, i-chondroitin, noma i-placebo ezigulini ezine-osteoarthritis. okhalweni noma idolo: ukuhlaziywa kwe-meta-analysis. BMJ 2010; 341: c4675. Buka okungaqondakali.
94. USawitzke, AD, Shi, H., Finco, MF, Dunlop, DD, Harris, CL, Singer, NG, Bradley, JD, Silver, D., Jackson, CG, Lane, NE, Oddis, CV, Wolfe, F. , Lisse, J., Furst, DE, Bingham, CO, Reda, DJ, Moskowitz, RW, Williams, HJ, noClegg, DO Clinical efficacy and safety of glucosamine, chondroitin sulphate, inhlanganisela yabo, i-celecoxib noma i-placebo ethathwe ukwelapha i-osteoarthritis wamadolo: imiphumela yeminyaka emi-2 evela ku-GAIT. UMnu. Ann. 2010; 69: 1459-1464. Buka okungaqondakali.
95. UJackson, CG, Plaas, AH, Sandy, JD, Hua, C., Kim-Rolands, S., Barnhill, JG, Harris, CL, noClegg, DO Ama-pharmacokinetics womuntu wokufaka ngomlomo i-glucosamine ne-chondroitin sulfate ethathwe ngokwahlukana noma ngokuhlangana. I-Osteoarthritis Cartilage 2010; 18: 297-302. Buka okungaqondakali.
96. U-Lee, Y. H., Woo, J. H., Choi, S. J., Ji, J. D., no-Song, G. G. Umphumela we-glucosamine noma i-chondroitin sulfate ekuqhubekeni kwe-osteoarthritis: ukuhlaziywa kwe-meta. IRheumatol Int 2010; 30: 357-363. Buka okungaqondakali.
97. I-Theoharides, T. C., Kempuraj, D., Vakali, S., ne-Sant, G. R. Ukwelashwa kwe-cystitis yesibindi / isifo esibuhlungu sesinye nge-CystoProtek - isithasiselo semvelo somenzeli womlomo omningi. Ingabe uJ Urol 2008; 15: 4410-4414. Buka okungaqondakali.
98. I-Dudics, V., Kunstar, A., Kovacs, J., Lakatos, T., Geher, P., Gomor, B., Monostori, E., no-Uher, F. Amandla weChondrogenic wamaseli we-mesenchymal stem avela ezigulini ezine-rheumatoid. i-arthritis ne-osteoarthritis: izilinganiso ohlelweni lwe-microculture. Amaseli izicubu.Izinhlelo 2009; 189: 307-316. Buka okungaqondakali.
99. UCahlin, B. J. noDahlstrom, L. Awukho umphumela we-glucosamine sulfate ku-osteoarthritis emajoyini we-temporomandibular - isifundo esingahleliwe, esilawulwayo, sesikhashana. I-Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2011; 112: 760-766. Buka okungaqondakali.
100. UShaygannejad, V., Janghorbani, M., Savoj, M. R., no-Ashtari, F. Imiphumela ye-adjunct glucosamine sulphate ekubuyiseleni-ekubuyiseleni phambili ukuqhubekela phambili kwe-sclerosis: ukutholwa kokuqala kwesilingo esilawulwa ngokungahleliwe, esilawulwa yi-placebo. I-Neurol Res 2010; 32: 981-985. Buka okungaqondakali.
101. U-Ostojic, S. M., Arsic, M., Prodanovic, S., Vukovic, J., noZlatanovic, ukuphathwa kukaM. Glucosamine kubagijimi: imiphumela ekululameni kokulimala kwamadolo okunamandla. I-Res Sports Med 2007; 15: 113-124. Buka okungaqondakali.
102. Rozendaal, RM, Uitterlinden, EJ, van Osch, GJ, Garling, EH, Willemsen, SP, Ginai, AZ, Verhaar, JA, Weinans, H., Koes, BW, and Bierma-Zeinstra, SM Effect of glucosamine sulphate on joint ukunciphisa isikhala, ubuhlungu nokusebenza kweziguli ezine-hip osteoarthritis; ukuhlaziywa kweqembu elincane lesilingo esilawulwa ngokungahleliwe. I-Osteoarthritis Cartilage 2009; 17: 427-432. Buka okungaqondakali.
103. UMarti-Bonmati, L., Sanz-Requena, R., Rodrigo, J. L., Alberich-Bayarri, A., noCarot, J. M. Glucosamine sulphate umphumela ku-patellar cartilage owonakele: ukutholwa kokuqala yi-pharmacokinetic modeling resonance magnetic. I-Eur Radiol 2009; 19: 1512-1518. Buka okungaqondakali.
104. URovati LC, uGiacovelli G, u-Annefeld N, no-al. Ucwaningo olukhulu, olungahleliwe, olulawulwa yi-placebo, oluyimpumputhe kabili lwe-glucosamine sulfate vs piroxocam kanye nokuhlangana kwabo ne-kinetics yomphumela oyimpawu ku-knee osteoarthritis. I-Osteoarth Cartilage 1994; 2 (suppl 1): 56.
105. INandhakumar J. Ukusebenza, ukubekezelelana, nokuphepha kwe-anti-inflammatory enezinto eziningi ezine-glucosamine hydrochloride vs glucosamine sulfate vs i-NSAID ekwelapheni i-knee osteoarthritis - isifundo esingahleliwe, esizoba khona, esimpumputhe kabili. I-Integr Med Clin J 2009; 8: 32-38.
106. UMuller-Fassbender, H., Bach, G. L., Haase, W., Rovati, L. C., noSetnikar, I. I-Glucosamine sulfate uma iqhathaniswa ne-ibuprofen e-osteoarthritis yamadolo. I-Osteoarthritis Cartilage 1994; 2: 61-69. Buka okungaqondakali.
107. Towheed, T. E. kanye no-Anastassiades, T. P. Ukwelashwa kwe-Glucosamine ye-osteoarthritis. UJ Rheumatol 1999; 26: 2294-2297. Buka okungaqondakali.
108. UZhang, W., Nuki, G., Moskowitz, RW, Abramson, S., Altman, RD, Arden, NK, Bierma-Zeinstra, S., Brandt, KD, Croft, P., Doherty, M., Dougados, M., Hochberg, M., Hunter, DJ, Kwoh, K., Lohmander, LS, noTugwell, P. OARSI izincomo zokuphathwa kwe-hip ne-knee osteoarthritis: ingxenye III: Izinguquko ebufakazini kulandela ukubuyekezwa okuhlelekile kokucwaninga okushicilelwe ngoJanuwari 2009. I-Osteoarthritis Cartilage 2010; 18: 476-499. Buka okungaqondakali.
109. UPeteren, SG, Beyer, N., Hansen, M., Holm, L., Aagaard, P., Mackey, AL, noKjaer, M. Isidakamizwa esiphikisayo sokulwa nokuvuvukala noma i-glucosamine sinciphise ubuhlungu namandla athuthukisiwe emisipha ngokuqeqeshwa kokumelana isilingo esilawulwa ngokungahleliwe seziguli zamadolo osteoarthritis. I-Arch Phys Med Rehabil 2011; 92: 1185-1193. Buka okungaqondakali.
110. UNoack, W., Fischer, M., Forster, K. K., Rovati, L. C., noSetnikar, I. I-Glucosamine sulfate e-osteoarthritis yamadolo. I-Osteoarthritis Cartilage 1994; 2: 51-59. Buka okungaqondakali.
111. UGiordano N, uFioravanti A, uPapakostas P, et al. Ukusebenza nokubekezelela i-glucosamine sulfate ekwelapheni i-knee osteoarthritis: isilingo esilawulwa ngokungahleliwe, esingaboni kabili, esilawulwa yi-placebo. ICurr Ther Res Clin Exp 2009; 70: 185-196. Buka okungaqondakali.
112. Yamamoto, T., Kukuminato, Y., Nui, I., Takada, R., Hirao, M., Kamimura, M., Saitou, H., Asakura, K., noKataura, A. [Ubudlelwano phakathi kwempova ye-birch ukungezwani komzimba kanye nomlomo kanye ne-pharyngeal hypersensitivity to izithelo]. UNippon Jibiinkoka Gakkai Kaiho 1995; 98: 1086-1091. Buka okungaqondakali.
113. UKawasaki T, Kurosawa H, Ikeda H, et al. Imiphumela eyengeziwe ye-glucosamine noma i-risedronate ekwelapheni i-osteoarthritis yamadolo kuhlangene nokuzivocavoca kwasekhaya: isilingo esingahle senziwe ngokungahleliwe sezinyanga eziyi-18. UJ Bone Miner Metab 2008; 26: 279-87. Buka okungaqondakali.
114. UNelson BA, uRobinson KA, uBuse MG. I-glucose ephezulu ne-glucosamine yenza ukumelana ne-insulin ngezinqubo ezahlukahlukene kuma-adipocyte e-3T3-L1. Isifo sikashukela 2000; 49: 981-91. Buka okungaqondakali.
115. UBaron AD, uZhu JS, uZhu JH, et al. I-Glucosamine inciphisa ukumelana ne-insulin ku-vivo ngokuthinta ukuhanjiswa kwe-GLUT 4 emisipheni yamathambo. Imiphumela yeshukela le-glucose. UJ Clin Invest 1995; 96: 2792-801. Buka okungaqondakali.
116. U-Eggertsen R, Andreasson A, Andren L. Azikho izinguquko zamazinga e-cholesterol ngomkhiqizo we-glucosamine otholakala ngokuthengisa ezigulini ezelashwa ngemithi yokwehlisa i-lipid: isivivinyo esilawulwayo, esingahleliwe, esivulekile. I-BMCPharmacol Toxicol 2012; 13: 10. Buka okungaqondakali.
117. U-Liu W, uLiu G, uPei F, et al. Isifo seKashin-Beck eSichuan, eChina: umbiko wesilingo esivula isilingo sokwelapha. UJ Clin Rheumatol 2012; 18: 8-14. Buka okungaqondakali.
118. UNakamura H, Masuko K, Yudoh K, et al. Imiphumela yokuphathwa kwe-glucosamine ezigulini ezinesifo samathambo. IRheumatol Int 2007; 27: 213-8. Buka okungaqondakali.
119. UBruyere O, Pavelka K, Rovati LC, et al. Ingqikithi yokufakwa ngokuhlanganyela ngemuva kokwelashwa kwe-glucosamine sulphate emadolweni i-osteoarthritis: imiphumela yokuhlolisiswa kweminyaka engu-8 kweziguli kusuka eminyakeni emibili edlule ye-3, izilingo ezilawulwa ngokungahleliwe, ezilawulwa yi-placebo. I-Osteoarthritis Cartilage 2008; 16: 254-60. Buka okungaqondakali.
120. UBijlsma JWJ, uLafeber FPJG. I-Glucosamine sulfate ku-osteoarthritis: Ijaji lisaphumile. U-Ann Intern Med 2008; 148: 315-6. Buka okungaqondakali.
121. Rozendaal RM, Koes BW, van Osch GJVM, et al. Umphumela we-glucosamine sulfate ku-hip osteoarthritis: Isivivinyo esingahleliwe. U-Ann Intern Med 2008; 148: 268-77. Buka okungaqondakali.
122. UPersiani S, uRotini R, uTrisolino G, et al. Ukugxila kwe-Synovial ne-plasma glucosamine ezigulini ze-osteoarthritic ezilandela i-oral crystalline glucosamine sulphate ekwelashweni kokwelapha. I-Osteoarthritis Cartilage 2007; 15: 764-72. Buka okungaqondakali.
123. I-Yue QY, iStrandell J, iMyrberg O. Ukusetshenziswa okuhambisanayo kwe-glucosamine kungahle kube nomphumela we-warfarin. Isikhungo Sokuqapha i-Uppsala. Kutholakala ku: www.who-umc.org/graphics/9722.pdf (Kufinyelelwe ngomhla ka-28 Ephreli 2008).
124. UKnudsen J, uSokol GH. Ukusebenzisana okungenzeka kwe-glucosamine-warfarin okuholele ekukhuleni kwesilinganiso esijwayelekile somhlaba jikelele: Umbiko wecala nokubuyekezwa kwemibhalo kanye nedatha ye-MedWatch. I-Pharmacotherapy 2008; 28: 540-8. Buka okungaqondakali.
125. UMuniyappa R, Karne RJ, Hall G, et al. I-Oral glucosamine yamaviki ayisithupha ngamanani avamile ayibangeli noma yenze kube nzima ukumelana ne-insulin noma ukungasebenzi kahle kwe-endothelial ezifundweni ezincikile noma ezikhuluphele. Isifo sikashukela 2006; 55: 3142-50. Buka okungaqondakali.
126. UTannock LR, Kirk EA, King VL, et al. Isengezo se-Glucosamine sisheshisa i-atherosclerosis yokuqala kodwa hhayi sekwephuzile kumagundane angenele we-LDL. J Izakhi 2006; 136: 2856-61. Buka okungaqondakali.
127. UPham T, uCornea A, uBlick KE, et al. I-Oral glucosamine ngemithamo esetshenziselwa ukwelapha i-osteoarthritis yandisa ukumelana ne-insulin. Ngingu-J Med Sci 2007; 333: 333-9. Buka okungaqondakali.
128. UMessier SP, uMihalko S, uLoeser RF, et al. I-Glucosamine / chondroitin ehlanganiswe nokuvivinya umzimba ekwelapheni i-knee osteoarthritis: isifundo sokuqala. I-Osteoarthritis Cartilage 2007; 15: 1256-66. Buka okungaqondakali.
129. IStumpf JL, iLin SW. Umphumela we-glucosamine ekulawuleni i-glucose. U-Ann Pharmacother 2006; 40: 694-8. Buka okungaqondakali.
130. UBush TM, uRayburn KS, uHolloway SW, et al.Ukusebenzisana okungahambi kahle phakathi kwezinto ezinamakhambi nezokudla kanye nemithi kadokotela: inhlolovo yomtholampilo. I-Ther Ther Health Med 2007; 13: 30-5. Buka okungaqondakali.
131. UTowheed TE, uMaxwell L, u-Anastassiades TP, et al. Ukwelashwa kwe-Glucosamine yokwelapha i-osteoarthritis. ICchrane Database Syst Rev 2005;: CD002946. Buka okungaqondakali.
132. Poolsup N, Suthisisang C, Channark P, Kittikulsuth W. Glucosamine ukwelashwa kwesikhathi eside kanye nokuqhubekela phambili kwamadolo i-osteoarthritis: ukubuyekezwa okuhlelekile kwezilingo ezilawulwa ngokungahleliwe. U-Ann Pharmacother 2005; 39: 1080-7. Buka okungaqondakali.
133. I-Qiu GX, i-Weng XS, uZhang K, et al. [Isivivinyo somtholampilo esimaphakathi nendawo, esingahleliwe, esilawulwayo se-glucosamine hydrochloride / sulfate ekwelapheni i-knee osteoarthritis]. UZhonghua Yi Xue Za Zhi 2005; 85: 3067-70. Buka okungaqondakali.
134. UClegg DO, uReda DJ, uHarris CL, et al. I-Glucosamine, i-chondroitin sulfate, kanye nalokhu okubili kuhlangene i-osteoarthritis yamadolo ebuhlungu. N Engl J Med 2006; 354: 795-808. Buka okungaqondakali.
135. UHerrero-Beaumont G, u-Ivorra JA, uDel Carmen Trabado M, et al. I-Glucosamine sulfate ekwelapheni izimpawu zamadolo e-osteoarthritis: isifundo esilawulwa ngokungahleliwe, esiyimpumputhe, esilawulwa yi-placebo sisebenzisa i-acetaminophen njengesiqhathanisi eseceleni. I-Arthritis Rheum 2007; 56: 555-67. Buka okungaqondakali.
136. I-Theodosakis J. Isivivinyo esilawulwa ngokungahleliwe, esiyimpumputhe kabili, se-placebo sokhilimu wama-topical oqukethe i-glucosamine sulfate, i-chondroitin sulfate, ne-camphor ye-osteoarthritis yamadolo. UJ Rheumatol 2004; 31: 826. Buka okungaqondakali.
137. UZhang W, Doherty M, Arden N, et al. Izincomo ezenzelwe ubufakazi be-EULAR zokuphathwa kwe-hip osteoarthritis: umbiko weqembu eliqokiwe le-EULAR Standing Committee for International Clinical Study Including Therapeutics (ESCISIT). U-Ann Rheum Dis 2005; 64: 669-81. Buka okungaqondakali.
138. I-Towheed TE, i-Anastassiades TP, uShea B, et al. Ukwelashwa kwe-Glucosamine yokwelapha i-osteoarthritis. ICchrane Database Syst Rev 2001; 1: CD002946. Buka okungaqondakali.
139. UMcAlindon T. Kungani izilingo zomtholampilo ze-glucosamine zingasasebenzi ngokufanayo? Rheum Dis Clin North Am 2003; 29: 789-801. Buka okungaqondakali.
140. UCibere J, uKopec JA, uThorne A, et al. Isivivinyo sokuyekisa i-glucosamine esilawulwa ngokungahleliwe, esingaboni kabili, esilawulwa nge-placebo ku-knee osteoarthritis. I-Arthritis Rheum 2004; 51: 738-45. Buka okungaqondakali.
141. UMcAlindon T, uFormica M, uLaValley M, et al. Ukusebenza kwe-glucosamine yezimpawu zamadolo i-osteoarthritis: imiphumela evela esivivinyweni esilawulwa ngokungahleliwe esilawulwa yi-intanethi esilawulwa ngokungahleliwe. NginguJ Med 2004; 117: 643-9. Buka okungaqondakali.
142. UBruyere O, Pavelka K, Rovati LC, et al. I-Glucosamine sulfate inciphisa ukuqhubekela phambili kwe-osteoarthritis kwabesifazane be-postmenopausal abane-knee osteoarthritis: ubufakazi obuvela ezifundweni ezimbili zeminyaka emithathu. Ukunqamuka kokuya esikhathini 2004; 11: 138-43. Buka okungaqondakali.
143. Okumpunga HC, Hutcheson PS, uSlavin RG. Ngabe i-glucosamine iphephile ezigulini ezinokungezwani kokudla kwasolwandle (incwadi) J Ukungezwani komzimba ne-Immunol 2004; 114: 459-60. Buka okungaqondakali.
144. UTannis AJ, uBarban J, uConquer JA. Umphumela we-glucosamine supplementation ekuzileni nasekungazameni ukudla kwe-plasma glucose kanye nokugxila kwe-serum insulin kubantu abaphilile. I-Osteoarthritis Cartilage 2004; 12: 506-11. Buka okungaqondakali.
145. UWeimann G, uLubenow N, uSelleng K, et al. I-Glucosamine sulfate ayihambelani nama-antibodies eziguli ezine-heparin-induced thrombocytopenia. I-Eur J Haematol 2001; 66: 195-9. Buka okungaqondakali.
146. UHughes R, uCarr A. Isivivinyo esilawulwa ngokungahleliwe, esingaboni kabili, esilawulwa nge-placebo se-glucosamine sulphate njenge-analgesic ku-osteoarthritis yamadolo. I-Rheumatology (Oxford) 2002; 41: 279-84. . Buka okungaqondakali.
147. URozenfeld V, uCrain JL, uCallahan AK. Ukwanda okungenzeka komphumela we-warfarin yi-glucosamine-chondroitin. NginguJ J Health Syst Pharm 2004; 61: 306-307. Buka okungaqondakali.
148. I-Towheed TE. Isimo samanje sokwelapha i-glucosamine ku-osteoarthritis. I-Arthritis Rheum 2003; 49: 601-4. Buka okungaqondakali.
149. Ilungu lePhalamende laseGuillaume, uPeretz A. Ukuhlangana okungenzeka phakathi kokwelapha i-glucosamine kanye nobuthi bezinso: phawula ngencwadi kaDanao-Camara. I-Arthritis Rheum 2001; 44: 2943-4. Buka okungaqondakali.
150. UDanao-Camara T. Imiphumela engemihle yokwelashwa nge-glucosamine ne-chondroitin. I-Arthritis Rheum 2000; 43: 2853. Buka okungaqondakali.
151. UCohen M, uWolfe R, uMai T, uLewis D. Isivivinyo esilawulwa ngokungahleliwe, esiyimpumputhe kabili, se-placebo sokhilimu owenziwe ngezihloko oqukethe i-glucosamine sulfate, i-chondroitin sulfate, ne-camphor ye-osteoarthritis yamadolo. J Rheumatol 2003; 30: 523-8 .. Buka okungaqondakali.
152. U-Yu JG, uBoies SM, u-Olefsky JM. Umphumela we-oral glucosamine sulfate ekuzweleni kwe-insulin ezifundweni zabantu. Ukunakekelwa yisifo sikashukela 2003; 26: 1941-2. Buka okungaqondakali.
153. I-Setnikar I, iRovati LC. Ukuncela, ukusabalalisa, imetabolism kanye nokukhishwa kweglucosamine sulfate. Ukubuyekeza. I-Arzneimittelforschung 2001; 51: 699-725. Buka okungaqondakali.
154. UHoffer LJ, uKaplan LN, uHamadeh MJ, et al. I-Sulphate ingalamula umphumela wokwelapha we-glucosamine sulfate. I-Metabolism 2001; 50: 767-70 .. Buka okungaqondakali.
155. Braham R, Dawson B, Goodman C. Umphumela we-glucosamine supplementation kubantu ababhekene nobuhlungu bamadolo obujwayelekile. UBr J Sports Med 2003; 37: 45-9. Buka okungaqondakali.
156. UScroggie DA, Albright A, uHarris MD. Umphumela we-glucosamine-chondroitin supplementation kumazinga we-hemoglobin we-glycosylated ezigulini ezinesifo sikashukela sohlobo 2: isilingo somtholampilo esilawulwa yi-placebo, esimpumputhe kabili, esingahleliwe. I-Arch Intern Med 2003; 163: 1587-90. Buka okungaqondakali.
157. URichy F, uBruyere O, u-Ethgen O, et al. Ukusebenza okuhlelekile nokwakheka kwe-glucosamine ne-chondroitin ku-knee osteoarthritis: ukuhlaziywa okuphelele kwe-meta. I-Arch Intern Med 2003; 163: 1514-22. Buka okungaqondakali.
158. USalvatore S, uHeuschkel R, uTomlin S, et al. Ucwaningo lomshayeli we-N-acetyl glucosamine, isisekelo sokudla okunomsoco we-glycosaminoglycan synthesis, ezigulini zesifo samathumbu esingapheli esihlasela izingane. I-Aliment Pharmacol Ther 2000; 14: 1567-79 .. Buka okungaqondakali.
159. UTallia AF, uCardone DA. Ukukhuphuka kwesifuba somoya okuhambisana nesengezo se-glucosamine-chondroitin. J Am Board Fam Pract 2002; 15: 481-4 .. Buka okungaqondakali.
160. UTiku ML, uNarla H, uKarry SK, et al. IGlucosamine Inhibits Advanced Lipoxidation Reaction and Chemical Modification of Lipoproteins by Scavenging Reactive Carbonyl Intermediates. I-American College of Rheumatology Meeting; Okthoba 25-29, 2002. Abstract 11.
161. U-Alvarez-Soria MA, uLargo R, uDiez-Ortego E, et al. I-Glucosamine Inhibits IL-1ß eyenziwe yi-NF-kappa B Ukwenza ku-Human Osteoarthritic chondrocytes. I-American College of Rheumatology Meeting; Okthoba 25-29, 2002. Abstract 118.
162. UGanu VA, Hu SI, uStrassman J, et al. Ama-inhibitor we-N-glycosylation anciphisa ukukhiqizwa okwenziwe nge-Cytokine kweMatrix Metalloproteinases, i-Nitric oxide, ne-PGE2 kusuka ku-Articular Chondrocytes: I-Candidate Mechanism ye-Chondroprotective Effects ye-d-Glucosamine. I-American College of Rheumatology Meeting; Okthoba 25-29, 2002. Abstract 616.
163. UDu XL, u-Edelstein D, uDimmeler S, et al. I-Hyperglycemia ivimbela umsebenzi we-endothelial nitric oxide synthase ngokuguqulwa kokuhumusha ngemuva kusiza se-Akt. UJ Clin Invest 2001; 108: 1341-8. Buka okungaqondakali.
164. UPavelka K, uGatterova J, u-Olejarova M, et al. Ukusetshenziswa kwe-Glucosamine sulfate nokubambezeleka kokuqhubekela phambili kwe-osteoarthritis yamadolo: Ucwaningo lweminyaka emithathu, olulawulwa ngokungahleliwe, olulawulwa yi-placebo, oluyimpumputhe kabili. I-Arch Intern Med 2002; 162: 2113-23. Buka okungaqondakali.
165. I-Adebowale AO, iCox DS, uLiang Z, et al. Ukuhlaziywa kokuqukethwe kwe-glucosamine ne-chondroitin sulphate kumikhiqizo emakethwayo kanye nokutholakala kwe-Caco-2 kwezinto zokusetshenziswa ze-chondroitin sulfate. UJANA 2000; 3: 37-44.
166. I-Bagasra O, i-Whittle P, i-Heins B, i-Pomerantz RJ. I-anti-human immunodeficiency virus hlobo 1 umsebenzi wama-monosaccharides ane-sulfated: ukuqhathanisa nama-polysaccharides ane-sulfated namanye ama-polyions. J Ukuthelela Dis 1991; 164: 1082-90. Buka okungaqondakali.
167. UNowak A, uSzczesniak L, uRychlewski T, et al. Amazinga e-Glucosamine kubantu abanesifo senhliziyo esineschemic abanesifo sikashukela sohlobo II nangaphandle kwaso. IPol Arch Med Wewn 1998; 100: 419-25. Buka okungaqondakali.
168. U-Olszewski AJ, uSzostak WB, uMcCully KS. I-Plasma glucosamine ne-galactosamine kusifo senhliziyo esibuhlungu. I-Atherosclerosis 1990; 82: 75-83. Buka okungaqondakali.
169. U-Yun J, uTomida A, uNagata K, uTsuruo T. Ukucindezelwa okulawulwa yi-Glucose kunikeza ukumelana ne-VP-16 kumaseli womdlavuza womuntu ngokuncipha kokwehla kwe-DNA topoisomerase II. I-Oncol Res 1995; 7: 583-90. Buka okungaqondakali.
170. UPouwels MJ, uJacobs JR, uSpan PN, et al. Ukumnika okwesikhashana esifushane i-glucosamine akuthinti ukuzwela kwe-insulin kubantu. UJ Clin Endocrinol Metab 2001; 86: 2099-103. Buka okungaqondakali.
171. UMonauni T, uZenti MG, uCretti A, et al. Imiphumela ye-glucosamine infusion ekusithekeni kwe-insulin kanye nesenzo se-insulin kubantu. Isifo sikashukela 2000; 49: 926-35. Buka okungaqondakali.
172. UDas A Jr, uHammad TA. Ukusebenza kwenhlanganisela ye-FCHG49 glucosamine hydrochloride, TRH122 low molecular weight sodium chondroitin sulfate and manganese ascorbate in the management of knee osteoarthritis. I-Osteoarthritis Cartilage 2000; 8: 343-50. Buka okungaqondakali.
173. IBhodi Yezokudla Nezokudla, Isikhungo Sezokwelapha. Ukufakwa Kwezikhombo Zezokudla ku-Vitamin A, Vitamin K, Arsenic, Boron, Chromium, Copper, Iodine, Iron, Manganese, Molybdenum, Nickel, Silicon, Vanadium, neZinc. Washington, DC: National Academy Press, 2002. Itholakala ku: www.nap.edu/books/0309072794/html/.
174. Ngabe i-glucosamine inyusa amazinga e-serum lipid nomfutho wegazi? Incwadi ka-Pharmacist's Letter / Prescriber's 2001; 17: 171115.
175. UReginster JY, uDeroisy R, uRovati LC, et al. Imiphumela yesikhathi eside ye-glucosamine sulfate ekuqhubekeni kwe-osteoarthritis: isilingo esilawulwa ngokungahleliwe, esilawulwa yi-placebo. ILancet 2001; 357: 251-6. Buka okungaqondakali.
176. I-Almada A, i-Harvey P, i-Platt K. Imiphumela ye-oral glucosamine sulphate ekuzileni i-insulin insulin index index (FIRI) kubantu abangasifo sikashukela. I-FASEB J 2000; 14: A750.
177. Leffler CT, Philippi AF, Leffler SG, et al. I-Glucosamine, i-chondroitin, ne-manganese ascorbate yesifo esihlanganayo esiwohlokayo emadolweni noma emuva okuphansi: isifundo esilawulwa ngokungahleliwe, esiyimpumputhe, esilawulwa yi-placebo. IMil Med 1999; 164: 85-91. Buka okungaqondakali.
178. Thie NM, Prasad NG, Major PW. Ukuhlolwa kwe-glucosamine sulfate kuqhathaniswa ne-ibuprofen ekwelapheni i-temporomandibular joint osteoarthritis: isilingo somtholampilo esilawulwa izimpumputhe esilawulwa izinyanga ezi-3. UJ Rheumatol 2001; 28: 1347-55. Buka okungaqondakali.
179. UShankar RR, uZhu JS, uBaron AD. Ukufakwa kwe-Glucosamine kumagundane kulingisa ukungasebenzi kahle kwe-beta-cell yesifo sikashukela esingancikile ku-insulin. IMetabolism 1998; 47: 573-7. Buka okungaqondakali.
180. URossetti L, uHawkins M, Chen W, et al. Ku-vivo glucosamine ukumnika kukhuthaza ukumelana ne-insulin kuma-normoglycemic kepha hhayi kumagundane we-hyperglycemic. UJ Clin Invest 1995; 96: 132-40. Buka okungaqondakali.
181. UBurton AF, noAnderson FH. Ukwehla kokufakwa kwe-14C-glucosamine ngokuhlobene ne-3H-N-acetyl glucosamine kumathumbu emathumbu eziguli ezinesifo samathumbu esivuthayo. NginguJ J Gastroenterol 1983; 78: 19-22. Buka okungaqondakali.
182. IBarclay TS, iTsourounis C, iMcCart GM. I-Glucosamine. U-Ann Pharmacother 1998; 32: 574-9. Buka okungaqondakali.
183. USettikar I, uPalumbo R, uCanali S, et al. I-Pharmacokinetics ye-glucosamine kumuntu. I-Arzneimittelforschung 1993; 43: 1109-13. Buka okungaqondakali.
184. UForster K, uSchmid K, uRovati L, et al. Ukwelashwa kwesikhathi eside kwe-osteoarthritis emnene ukuya kokulinganiselayo yamadolo nge-glucosamine sulfate- isifundo somtholampilo esilawulwa ngokungahleliwe, esiphindwe kabili. I-Eur J Clin Pharmacol 1996; 50: 542.
185. I-Reichelt A. Ukusebenza nokuphepha kwe-intramuscular glucosamine sulfate ku-osteoarthritis yamadolo. Ucwaningo olwenziwa ngokungahleliwe, olulawulwa yi-placebo, oluyimpumputhe kabili. I-Arzneimittelforschung 1994; 44: 75-80. Buka okungaqondakali.
186. I-Qiu GX, uGao SN, uGiacovelli G, et al. Ukusebenza nokuphepha kwe-glucosamine sulfate kuqhathaniswa ne-ibuprofen ezigulini ezine-osteoarthritis yamadolo. I-Arzneimittelforschung 1998; 48: 469-74. Buka okungaqondakali.
187. UPujalte JM, uLlavore EP, uYlescupidez FR. Ukuhlolwa komtholampilo okungaboni kabili komlomo we-glucosamine sulphate ekwelashweni okuyisisekelo kwe-osteoarthrosis. ICurr Med Res Opin 1980; 7: 110-4. Buka okungaqondakali.
188. I-Lopes Vaz A. I-blind-blind, ukuhlolwa komtholampilo ngokusebenza okuhlobene kwe-ibuprofen ne-glucosamine sulphate ekuphathweni kwe-osteoarthrosis yamadolo ezigulini ezingaphandle. ICurr Med Res Opin 1982; 8: 145-9. Buka okungaqondakali.
189. I-da Camara CC, i-GV engenantambo. I-Glucosamine sulfate ye-osteoarthritis. U-Ann Pharmacother 1998; 32: 580-7. Buka okungaqondakali.
190. UDrovanti A, uBignamini AA, uRovati AL. Umsebenzi wokwelapha we-oral glucosamine sulfate ku-osteoarthrosis: uphenyo olulawulwa yi-placebo olulawulwa kabili. Umtholampilo Ther 1980; 3: 260-72. Buka okungaqondakali.
191. UMcAlindon TE, iLungu lePhalamende laseLaValley, uGulin JP, uFelson DT. I-Glucosamine ne-chondroitin yokwelashwa kwe-osteoarthritis: ukuhlolwa kwekhwalithi okuhlelekile nokuhlaziywa kwe-meta. I-JAMA 2000; 283: 1469-75. Buka okungaqondakali.
192. IHupt JB, McMillan R, Wein C, Paget-Dellio SD. Umphumela we-glucosamine hydrochloride ekwelapheni ubuhlungu be-osteoarthritis yamadolo. UJ Rheumatol 1999; 26: 2423-30. Buka okungaqondakali.
193. URindone JP, uHiller D, uCollacott E, et al. Isivivinyo esingahleliwe, esilawulwayo se-glucosamine ekwelapheni i-osteoarthritis yamadolo. ENtshonalanga J Med 2000; 172: 91-4. Buka okungaqondakali.
194. UFoerster KK, uSchmid K, uRovati LC. Ukusebenza kwe-glucosamine sulfate ku-osteoarthritis yomgogodla we-lumbar: isifundo esilawulwa yi-placebo, esingahleliwe, esingaboni kabili. U-Am Coll Rheumatol 64th Ann Scientific Mtg, Philadelphia, PA: 2000; Okthoba 29- Nov 2: i-abstract 1613.
195. UKim YB, uZhu JS, uZierath JR, et al. Ukufakwa kwe-Glucosamine kumagundane kuphazamisa ngokushesha ukuvuselelwa kwe-insulin ye-phosphoinositide 3-kinase kepha akuguquli ukwenziwa kwe-Akt / protein kinase B emisipha yamathambo. Isifo sikashukela 1999; 48: 310-20. Buka okungaqondakali.
196. UHolmang A, uNilsson C, uNiklasson M, et al. Ukwenziwa kwe-insulin ukumelana yi-glucosamine kunciphisa ukugeleza kwegazi kepha hhayi amazinga we-glucose noma i-insulin. Isifo sikashukela 1999; 48: 106-11. Buka okungaqondakali.
197. UGiaccari A, uMorviducci L, uZorretta D, et al. Emiphumeleni ye-vivo ye-glucosamine ekusithekeni kwe-insulin nokuzwela kwe-insulin kumagundane: ukuhambisana okungenzeka nezimpendulo ezingalungile ku-hyperglycaemia engapheli. Isifo sikashukela 1995; 38: 518-24. Buka okungaqondakali.
198. I-Balkan B, i-Dunning BE. I-Glucosamine inqanda i-glucokinase in vitro futhi ikhiqize ukukhubazeka okuqondene noshukela we-vivo insulin secretion kumagundane. Isifo sikashukela 1994; 43: 1173-9. Buka okungaqondakali.
199. U-Adams ME. Thayipha nge-glucosamine. ILancet 1999; 354: 353-4. Buka okungaqondakali.

Kugcine ukubuyekezwa - 03/03/2021